349 related articles for article (PubMed ID: 30896772)
21. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
22. Autoantibodies to transducin in a patient with melanoma-associated retinopathy.
Potter MJ; Adamus G; Szabo SM; Lee R; Mohaseb K; Behn D
Am J Ophthalmol; 2002 Jul; 134(1):128-30. PubMed ID: 12095824
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
24. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
25. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
26. TREATMENT OF BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION WITH INTRAVITREAL STEROID IMPLANTS.
Gemperline TP; Smith BT
Retin Cases Brief Rep; 2022 Jul; 16(4):461-465. PubMed ID: 32649362
[TBL] [Abstract][Full Text] [Related]
27. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
28. SAFETY AND FEASIBILITY OF A NOVEL 25-GAUGE BIODEGRADABLE IMPLANT OF DEXAMETHASONE FOR TREATMENT OF MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION: A PHASE I CLINICAL TRIAL.
Cunha RB; Siqueira RC; Messias A; Scott IU; Fialho SL; Cunha-Junior ADS; Jorge R
Retin Cases Brief Rep; 2018 Winter; 12(1):50-58. PubMed ID: 27632583
[TBL] [Abstract][Full Text] [Related]
29. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
30. Severe course of cutaneous melanoma associated paraneoplastic retinopathy.
Kellner U; Bornfeld N; Foerster MH
Br J Ophthalmol; 1995 Aug; 79(8):746-52. PubMed ID: 7547786
[TBL] [Abstract][Full Text] [Related]
31. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
32. Fluocinolone acetonide intravitreal implant (Retisert
Leinonen S; Immonen I; Kotaniemi K
Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
[TBL] [Abstract][Full Text] [Related]
33. Melanoma-associated retinopathy associated with intranasal melanoma.
Machida S; Ohguro H; Tateda M; Sato H; Kurosaka D
Doc Ophthalmol; 2011 Jun; 122(3):191-7. PubMed ID: 21537930
[TBL] [Abstract][Full Text] [Related]
34. Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss.
Carboni G; Forma G; Bond AD; Adamus G; Iannaccone A
Doc Ophthalmol; 2012 Aug; 125(1):63-70. PubMed ID: 22569848
[TBL] [Abstract][Full Text] [Related]
35. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
[TBL] [Abstract][Full Text] [Related]
36. [Paraneoplastic retinopathy].
Liu Y; Lei B
Zhonghua Yan Ke Za Zhi; 2012 Jul; 48(7):653-6. PubMed ID: 22943872
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous melanoma-associated retinopathy with retinal periphlebitis.
Remulla JF; Pineda R; Gaudio AR; Milam AH
Arch Ophthalmol; 1995 Jul; 113(7):854-5. PubMed ID: 7605271
[No Abstract] [Full Text] [Related]
38. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
39. INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY: Report of Preliminary Findings.
Singaravelu J; Oakey ZB; Wrenn JM; Singh AD
Retina; 2023 Aug; 43(8):1364-1369. PubMed ID: 37027785
[TBL] [Abstract][Full Text] [Related]
40. Melanoma-associated retinopathy.
Elsheikh S; Gurney SP; Burdon MA
Clin Exp Dermatol; 2020 Mar; 45(2):147-152. PubMed ID: 31742740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
